Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Long-Term Investments (2021)

Aligos Therapeutics' Long-Term Investments history spans 1 years, with the latest figure at $15.1 million for Q4 2021.

  • For Q4 2021, Long-Term Investments changed N/A year-over-year to $15.1 million; the TTM value through Dec 2021 reached $15.1 million, changed N/A, while the annual FY2021 figure was $15.1 million, N/A changed from the prior year.
  • Long-Term Investments reached $15.1 million in Q4 2021 per ALGS's latest filing, up from $492000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $15.1 million in Q4 2021 to a low of $492000.0 in Q3 2021.